483
Sciegen Pharmaceuticals IncFDA 483 - Sciegen Pharmaceuticals Inc - January 09, 2015
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Sciegen Pharmaceuticals Inc. in Hauppauge, NY, revealed that the firm's quality control unit procedures were not fully followed. Specifically, a laboratory investigation into duplicate sample sets for Metformin Hydrochloride Tablets was deemed inadequate. The firm failed to determine the root cause of the event and did not conduct a comprehensive review of electronic files and associated audit trails.
Open in Dashboard
ID · 5e31791b-c59c-42d6-8153-31d0bd380825